BioMarin Pharmaceutical IncNASDAQ:BMRN
- LAST PRICE66.0300
- TODAY'S CHANGE (%)0.6100 (0.9324%)
- Bid / Lots62.5000/ 2
- Ask / Lots66.3000/ 4
- Open / Previous Close65.3300 / 65.4200
- Day Range
- 52 Week Range
- Volume699,132
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMRN |
|---|---|---|
| 09:32 ET | 13805 | 65.46 |
| 09:35 ET | 100 | 65.505 |
| 09:37 ET | 300 | 65.57 |
| 09:39 ET | 1200 | 65.47 |
| 09:42 ET | 1906 | 65.35 |
| 09:44 ET | 1200 | 65.56 |
| 09:46 ET | 3275 | 65.345 |
| 09:48 ET | 400 | 65.28 |
| 09:50 ET | 5093 | 65.285 |
| 09:51 ET | 1718 | 65.37 |
| 09:53 ET | 1677 | 65.345 |
| 09:55 ET | 800 | 65.313 |
| 09:57 ET | 1942 | 65.33 |
| 10:00 ET | 911 | 65.33 |
| 10:02 ET | 2945 | 65.36 |
| 10:04 ET | 1638 | 65.4 |
| 10:06 ET | 200 | 65.42 |
| 10:08 ET | 1585 | 65.48 |
| 10:09 ET | 1791 | 65.425 |
| 10:11 ET | 850 | 65.62 |
| 10:13 ET | 3067 | 65.54 |
| 10:15 ET | 2128 | 65.57 |
| 10:18 ET | 1473 | 65.51 |
| 10:20 ET | 100 | 65.59 |
| 10:22 ET | 1166 | 65.48 |
| 10:24 ET | 978 | 65.43 |
| 10:26 ET | 2624 | 65.565 |
| 10:27 ET | 1919 | 65.53 |
| 10:29 ET | 4961 | 65.6 |
| 10:31 ET | 200 | 65.58 |
| 10:33 ET | 915 | 65.5801 |
| 10:36 ET | 100 | 65.575 |
| 10:38 ET | 1206 | 65.585 |
| 10:40 ET | 1600 | 65.59 |
| 10:42 ET | 500 | 65.63 |
| 10:44 ET | 4153 | 65.64 |
| 10:45 ET | 110 | 65.65 |
| 10:47 ET | 1511 | 65.74 |
| 10:49 ET | 800 | 65.7 |
| 10:51 ET | 300 | 65.725 |
| 10:54 ET | 1913 | 65.8 |
| 10:56 ET | 3606 | 65.79 |
| 10:58 ET | 600 | 65.825 |
| 11:00 ET | 1312 | 65.825 |
| 11:02 ET | 500 | 65.86 |
| 11:03 ET | 1000 | 65.86 |
| 11:05 ET | 300 | 65.86 |
| 11:07 ET | 2558 | 65.88 |
| 11:09 ET | 2421 | 65.835 |
| 11:12 ET | 3765 | 65.875 |
| 11:14 ET | 9907 | 65.705 |
| 11:16 ET | 2780 | 65.7244 |
| 11:18 ET | 3325 | 65.77 |
| 11:20 ET | 912 | 65.75 |
| 11:21 ET | 18227 | 65.78 |
| 11:23 ET | 3000 | 65.78 |
| 11:25 ET | 10030 | 65.83 |
| 11:27 ET | 981 | 65.78 |
| 11:30 ET | 10488 | 65.72 |
| 11:32 ET | 400 | 65.69 |
| 11:34 ET | 465 | 65.725 |
| 11:36 ET | 552 | 65.6881 |
| 11:38 ET | 2524 | 65.735 |
| 11:39 ET | 2660 | 65.755 |
| 11:41 ET | 600 | 65.78 |
| 11:43 ET | 1500 | 65.78 |
| 11:45 ET | 1700 | 65.755 |
| 11:48 ET | 400 | 65.71 |
| 11:50 ET | 6682 | 65.76 |
| 11:52 ET | 1003 | 65.79 |
| 11:54 ET | 1427 | 65.73 |
| 11:56 ET | 1815 | 65.795 |
| 11:57 ET | 600 | 65.79 |
| 11:59 ET | 900 | 65.78 |
| 12:01 ET | 2733 | 65.817 |
| 12:03 ET | 700 | 65.8142 |
| 12:06 ET | 800 | 65.815 |
| 12:08 ET | 1900 | 65.825 |
| 12:10 ET | 1262 | 65.84 |
| 12:12 ET | 1213 | 65.87 |
| 12:14 ET | 5243 | 65.9 |
| 12:15 ET | 1463 | 65.925 |
| 12:17 ET | 1363 | 65.83 |
| 12:19 ET | 700 | 65.8218 |
| 12:21 ET | 2734 | 65.895 |
| 12:24 ET | 1050 | 65.9122 |
| 12:26 ET | 1205 | 65.93 |
| 12:28 ET | 338 | 65.97 |
| 12:30 ET | 2567 | 65.975 |
| 12:32 ET | 2553 | 65.965 |
| 12:33 ET | 5136 | 66.05 |
| 12:35 ET | 1000 | 66.02 |
| 12:37 ET | 6603 | 66.05 |
| 12:39 ET | 1875 | 66.001 |
| 12:42 ET | 2544 | 66.025 |
| 12:44 ET | 2164 | 66 |
| 12:46 ET | 5288 | 66.04 |
| 12:48 ET | 1999 | 66.035 |
| 12:50 ET | 4079 | 66.06 |
| 12:51 ET | 3528 | 66.02 |
| 12:53 ET | 12331 | 66.155 |
| 12:55 ET | 15307 | 66.035 |
| 12:57 ET | 13718 | 66.055 |
| 01:00 ET | 237172 | 66.03 |
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
Nov 15, 2024
DJ BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research, from 5:26AM ET on Friday Nov 15, 2024 by Dow Jones
5:26AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 6, 2024
BioMarin to Participate in Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 30, 2024
DJ BioMarin Pharmaceutical Is Maintained at Neutral by Citigroup, from 2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones
2:44PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity, from 1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioMarin Pharmaceutical Inc | 12.4B | 39.7x | --- |
Exact Sciences Corp | 11.4B | -53.0x | --- |
Neurocrine Biosciences Inc | 13.0B | 33.9x | +62.04% |
United Therapeutics Corp | 16.8B | 16.3x | +8.22% |
Medpace Holdings Inc | 10.4B | 29.8x | +35.10% |
Qiagen NV | 9.7B | 106.4x | +12.66% |
Company Information
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Contact Information
- Headquarters
- 105 Digital DriveNOVATO, CA, United States 94949
- Phone
- 415-505-6700
- Fax
- 415-382-7889
Executives
- Non-Executive Independent Chairman of the Board
- Richard Meier
- President, Chief Executive Officer, Director
- Alexander Hardy
- Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer
- Brian Mueller
- President - Worldwide Research and Development
- Henry Fuchs
- Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
- C. Greg Guyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.4B |
|---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 190.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $1.66 |
Book Value | $26.25 |
P/E Ratio | 39.7x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 29.3x |
Operating Margin | 11.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
